Racial and Ethnic Disparities in Buprenorphine and Naloxone among Medicaid Beneficiaries after Emergency Department Visits and Hospitalizations
Authors:
- 29 September 2026
- journal article
- research article
- Published by Springer Nature in Journal of General Internal Medicine
- p. 1-11
Abstract
No abstract availableKeywords
Funding Information
- National Institute on Drug Abuse (UH3DA047003)
This publication has 35 references indexed in Scilit:
- Emergency Department Access to Buprenorphine for Opioid Use DisorderJAMA Network Open, 2024
- State- and County-Level Geographic Variation in Opioid Use Disorder, Medication Treatment, and Opioid-Related Overdose Among Medicaid EnrolleesJAMA Health Forum, 2023
- Coverage and Prior Authorization Policies for Medications for Opioid Use Disorder in Medicaid Managed CareJAMA Health Forum, 2022
- Trends and Disparities in Access to Buprenorphine Treatment Following an Opioid-Related Emergency Department Visit Among an Insured Cohort, 2014-2020JAMA Network Open, 2022
- Use of Medications for Treatment of Opioid Use Disorder Among US Medicaid Enrollees in 11 States, 2014-2018JAMA, 2021
- Incidence of Treatment for Opioid Use Disorder Following Nonfatal Overdose in Commercially Insured PatientsJAMA Network Open, 2020
- Association of Racial/Ethnic Segregation With Treatment Capacity for Opioid Use Disorder in Counties in the United StatesJAMA Network Open, 2020
- Comparative Effectiveness of Different Treatment Pathways for Opioid Use DisorderJAMA Network Open, 2020
- Changes in Buprenorphine-Naloxone and Opioid Pain Reliever Prescriptions After the Affordable Care Act Medicaid ExpansionJAMA Network Open, 2018
- Emergency Department–Initiated Buprenorphine/Naloxone Treatment for Opioid DependenceJAMA, 2015